ArticleCancer chemotherapy and pharmacology2025
A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors.
Alice P Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.